Skip to main content

Today's Health Winners and Losers

Insmed falls after filing a registration statement to sell $75 million in stock.

Shares of



were among the worst-performing health-related stocks Monday, falling 7% after the biopharmaceutical company filed a $75 million shelf registration statement with the

Securities and Exchange Commission


The company seeks to sell up to $75 million in stock, preferred stock or warrants for common or preferred stock. "This shelf registration statement is intended to give Insmed flexibility to take advantage of financing opportunities when and if deemed appropriate by the company," it said. The company will use proceeds from the offerings for general purposes. Shares were trading down 17 cents to $2.16.



rose 1% after the company's generic muscle relaxant received Food and Drug Administration approval. The 5-milligram tablets are the generic equivalent to Flexeril, marketed by

Johnson & Johnson's


McNeil unit. Sales of 5-milligram Flexeril tablets were about $93 million for the 12-month period ended June 30, Mylan said. The company plans to begin shipping the tablets immediately. Shares were trading up 25 cents to $21.57.

Shares of



fell slightly after the nutritional supplements company posted January sales data. The company said that sales came in at $165 million, up about 9% from $151 million in January 2005. Sales at the company's Vitamin World unit rose to $22 million from $17 million a year ago, while sales at Puritan's Pride rose to $23 million from $19 million. The company's European sales, as measured by its Holland & Barrett and GNC (U.K.) brands, fell to $48 million from $50 million a year ago. Shares were trading down 2 cents to $19.50.



fell 2% after the company announced the completion of its stock offering. The company sold about 7.5 million shares, including 975,000 shares to cover over-allotments, at $16 apiece, resulting in gross proceeds of about $119.6 million. The company plans to use proceeds from the offering to fund general corporate needs. Shares were trading down 36 cents to $16.19.

Other health care volume movers included



, down 13 cents to $25.15;



, up 12 cents to $3.18;



, down 1 cent to $18.76;

Bristol-Myers Squibb


, up 20 cents to $22.46;



, down 59 cents to $74.03;



, down 34 cents to $14.93;

Boston Scientific


, down 25 cents to $21.55;



, down 43 cents to $33.96; and

Gilead Sciences


, down 45 cents to $60.25.